| Literature DB >> 35191714 |
Yun-Hao Ma1, Wan-Tong Ma1, Zhong-Kun Zhou1, Xiu Huang1, Xin-Rong Jiang1, Kang-Jia Du1, Meng-Ze Sun1, Hao Zhang1, Hong Fang1, Yi Zhao1, Hong-Mei Zhu1, Huan-Xiang Liu1, Peng Chen1, Ying-Qian Liu1.
Abstract
Neocryptolepine derivatives have attracted great interest because of their unique cytotoxic activity. 8-Fluoroneocryptolepine (8FNC) was synthesized, and its cytotoxicity was evaluated by MTT assay in AGS gastric cancer cells and gastric mucosa GES-1 cells. 8-Fluoroneocryptolepine showed greater selectivity and cytotoxicity to AGS cells than the cisplatin (CIS) and fluorouracil (5-Fu) commonly used in clinical treatment of gastric cancer. Most importantly, we significantly improved the cytotoxic effect of 8FNC against AGS cells by structural modification and reduced the cytotoxicity against GES-1 cells compared with neocryptolepine. We further evaluated the activity of 8FNC against AGS cells in vitro. Our results indicate that 8FNC arrests the AGS cell cycle in the G2/M phase, reduces the mitochondrial membrane potential of AGS cells, and drives the initiation of apoptotic body formation in 8FNC-induced apoptosis. Moreover, 8FNC exhibits strong inhibitory effects on AGS cell migration. Studies on the molecular mechanisms of the cytotoxic activities of 8FNC revealed that it may play a significant role in the inhibitory effect on AGS human gastric cancer cells through the PI3K/AKT signaling pathway. In conclusion, 8FNC may become a promising lead compound in the development of potential clinical drug candidates for the treatment of gastric cancer.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35191714 DOI: 10.1021/acs.jnatprod.1c01078
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050